NY-ESO-1 expression in sarcomas a diagnostic marker and immunotherapy target

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1409-1410

  Lai, Jin Ping ^a   Rosenberg, Avi Z ^a   Miettinen, Markku M ^a   Lee, Chyi Chia R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer testis antigen; Clinical trial; Diagnostic marker; Immunotherapy; Melanoma; NY ESO 1; Sarcomas; Synovial sarcoma; T cell receptor; Therapeutic target

Indexed keywords

NY ESO 1 ANTIGEN;

ALVEOLAR SOFT PART SARCOMA; ANGIOSARCOMA; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; CANCER IMMUNOTHERAPY; CELL DEDIFFERENTIATION; CHONDROSARCOMA; COHORT ANALYSIS; DERMATOFIBROSARCOMA PROTUBERANS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG TARGETING; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; HEMANGIOPERICYTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEIOMYOSARCOMA; LIPOSARCOMA; MALIGNANT MESOTHELIOMA; MELANOMA; MESENCHYMOMA; METASTASIS; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; MYXOSARCOMA; NERVE SHEATH TUMOR; NEURILEMOMA; NOTE; OSTEOSARCOMA; PRIORITY JOURNAL; RECURRENT CANCER; RHABDOMYOSARCOMA; SARCOMA; SENSITIVITY AND SPECIFICITY; SOLITARY FIBROUS TUMOR; SPINDLE CELL SARCOMA; SYNOVIAL SARCOMA; TREATMENT RESPONSE; TUMOR BIOPSY;

EID: 84876321822     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21059     Document Type: Note

References (9)

1. Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 2001; 85:713-20; PMID:11531257; http://dx.doi.org/10.1054/bjoc.2001.1974.
2. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29:917-24.
3. Jungbluth AA, Antonescu CR, Busam KJ, Iversen K, Kolb D, Coplan K, et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 2001; 94:252-6.
4. Lai JP, Robbins PF, Raffeld M, Aung PP, Tsokos M, Rosenberg SA, et al. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol 2012; 25:854-8.
5. Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94:1914-8.
6. Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol 2000; 165:1153-9.
7. Knuth A, Jäger D, Jäger E. Cancer immunotherapy in clinical oncology. Cancer Chemother Pharmacol 2000; 46:46-51.
8. Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, et al. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer 2012.
9. Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti S, Ferrari A, et al. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2007; 109:2522-31.